ConductScience.org, home
FDX1: ferredoxin 1
API referenceFor AI assistants

Gene · 2230

Papers1,417

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 1,417

Download this page as JSON
TitleJournalYearPMIDFound bySource
SUMOylation of PGAM2 regulates mitochondrial metabolism and cuproptosis-related damage during boar sperm cryoinjury.Theriogenology202742810240PubTator, text miningPubMed
FDX1-short proteoform induces caspase-independent cell death in tumor cells.Cell Death Differ202642816659PubTator, text miningPubMed
Roles of cuproptosis in central nervous system tumors: from molecular mechanisms to therapeutic prospects.Front Cell Dev Biol202642812787PubTator, text miningPubMed
Targeting FDX1 with oridonin triggers cuproptosis and inhibits tumor progression in nasopharyngeal carcinoma.Int J Biochem Cell Biol202642800577PubTator, text miningPubMed
Copper-regulated cell death after spinal cord injury: evidence boundaries for non-coding RNA, epigenetics and cuproptosis.Front Mol Neurosci202642787557PubTator, text miningPubMed
Cuproptosis: a novel mechanism linking placental metabolic stress to trophoblast injury in preeclampsia.Front Endocrinol (Lausanne)202642780476PubTator, text miningPubMed
Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin-elesclomol combination therapy.
Acta Pharm Sin B202642764935PubTator, text miningPubMed
SF1 regulates the transcription of FDX1 to promote cuproptosis in pediatric sepsis-related acute lung injury by interacting with cJUN.Biol Direct202642764381PubTator, text miningPubMed
SOX2 Inhibits Cuproptosis to Affect Cisplatin Resistance in Non-Small Cell Lung Cancer by Activating the Wnt/ATP7B Signaling Pathway.Kaohsiung J Med Sci202642757550PubTator, text miningPubMed
Cuproptosis in cerebrovascular diseases: Mechanisms and advances in targeted therapeutic strategies.Brain Res Bull202642754178PubTator, text miningPubMed
Mint3 suppresses cuproptosis by modulating the AHR signalling pathway to facilitate the progression of hepatocellular carcinoma.Sci China Life Sci202642734688PubTator, text miningPubMed
NBR1-Mediated Autophagic Degradation of YTHDF1 Curtails FDX1 Translation to Drive Concurrent Multikinase Inhibitor Resistance and Cuproptosis Tolerance.Cancer Commun (Lond)202642729649PubTator, text miningPubMed
Cuproptosis and copper metabolism regulate hepatocellular carcinoma progression and therapeutic response to sorafenib.Exp Cell Res202642716418PubTator, text miningPubMed
A copper-based nanotherapeutic overcomes multidrug- resistant breast cancer by blocking drug efflux and triggering cuproptosis.Colloids Surf B Biointerfaces202642696812PubTator, text miningPubMed
Copper, cuproptosis, and cancer: biology concepts of a novel cell death.Apoptosis202642693224PubTator, text miningPubMed
Cuproptosis: a novel mechanism and 3PM-oriented therapeutic strategy for cancer.EPMA J202642682874PubTator, text miningPubMed
UBE2S Promotes KIRC Progression by Regulating CDC20 Expression and Suppressing FDX1-Mediated Cuproptosis, While Promoting M2 Macrophage Polarization.Mol Carcinog202642669192PubTator, text miningPubMed
Functional role of LAMC1 in modulating cuproptosis in glioma cells.Biochim Biophys Acta Mol Cell Res202642665028PubTator, text miningPubMed
Copper Metabolism-Related Cell Death in Kidney Diseases: Molecular Mechanisms, Disease-Specific Evidence, and Translational Implications.Int J Mol Sci202642653078PubTator, text miningPubMed
Copper homeostasis and organelle-dependent mechanisms in bone metabolism: implications for osteoporosis therapy.Front Cell Dev Biol202642639305PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/2230/papers

API referenceFor AI assistants